---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-042728"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2024-10-11T23:59:59+00:00"
generated_at: "2026-05-30T15:28:30.055369+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics board requires shareholder approval for stock option repricing

## Summary
- Board approved Amendment No. 1 to the 2020 Stock Option and Incentive Plan on Oct 7, 2024.
- Amendment requires stockholder approval for any reduction in exercise price or repricing of stock options or SARs.
- Previous administrator authority to reprice without stockholder approval is removed.
- Amendment is effective immediately and does not require stockholder approval.

## SEC filing metadata
- accession: 0001628280-24-042728
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2024-10-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828024042728/0001628280-24-042728-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828024042728/cccc-20241011.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-042728
- JSON: https://secwatch.observer/filing/0001628280-24-042728.json
- Plain text: https://secwatch.observer/filing/0001628280-24-042728.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.